St Georges Hospital, Blackshaw Road, Tooting, London SW170QT, UK.
Expert Opin Pharmacother. 2010 Aug;11(11):1915-23. doi: 10.1517/14656566.2010.494180.
At present there is no standard treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma who progress following second-line therapy. Anthracyclines are highly active drugs, but their use in this setting is limited by cumulative cardiac toxicity. Pixantrone is a new aza-anthracenedione structurally similar to mitoxantrone and anthracyclines. This compound has been developed to minimize cardiac toxicity without reducing efficacy.
This review summarizes the preclinical and clinical trial data for the use of pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
An overview of the mechanism of action of pixantrone, preclinical data, clinical efficacy, safety data and future developments for this compound.
Pixantrone has been shown to be superior to other single-agent therapies for the salvage treatment of relapsed/refractory aggressive non-Hodgkin lymphoma. The pixantrone application will be submitted to the regulatory authorities in the USA and in Europe.
目前，对于二线治疗后进展的复发或难治性侵袭性非霍奇金淋巴瘤患者，尚无标准治疗方法。蒽环类药物具有高度活性，但由于累积性心脏毒性，其在该治疗环境中的应用受到限制。比柔比星是一种新型的氮杂蒽二酮，在结构上与米托蒽醌和蒽环类药物相似。该化合物的开发旨在在不降低疗效的情况下，最大限度地降低心脏毒性。
这篇综述总结了比柔比星在治疗侵袭性非霍奇金淋巴瘤中的应用的临床前和临床试验数据。
比柔比星的作用机制、临床前数据、临床疗效、安全性数据以及该化合物的未来发展概述。
比柔比星已被证明优于其他单一药物疗法，可用于挽救治疗复发/难治性侵袭性非霍奇金淋巴瘤。比柔比星的应用将提交给美国和欧洲的监管机构。
